Introduction
This table presents a structured comparison of the main contraceptive methods, with emphasis on efficacy, duration of use, menstrual impact, return to fertility and relevant contraindications.
Non-hormonal methods — copper IUD
Starting with non-hormonal methods, the copper IUD stands out as a highly effective method, with efficacy close to 99% and a duration of up to 12 years. Return to fertility is immediate and there are no hormonal contraindications, although menstrual flow may increase and dysmenorrhoea may occur — aspects that should be anticipated with the patient.
Hormonal intrauterine systems
Next are hormonal intrauterine systems, available with different levonorgestrel doses (52 mg, 19.5 mg and 13.5 mg). These devices also have high efficacy, with duration ranging from 3 to 8 years depending on the formulation. In addition to providing robust contraception, they tend to significantly reduce menstrual flow, leading to hypomenorrhoea or amenorrhoea in many users, which is a relevant advantage in women with menorrhagia. They are compatible with breastfeeding and fertility returns immediately after removal. The main contraindications include active breast cancer, severe cirrhosis and unexplained bleeding.
Long-acting progestogens — implant and injectable
The subdermal implant and medroxyprogesterone injectable are progestogen-only alternatives. The implant has high efficacy, prolonged use for up to three years and irregular spotting as its most notable adverse effect. The injectable, in turn, has adequate efficacy and may induce amenorrhoea, but with an important detail: return to fertility may be delayed, occurring around nine to ten months after the last administration. Both are compatible with breastfeeding and avoid the thrombotic risks associated with oestrogens.
Combined methods — oestrogen + progestogen
Among combined methods containing oestrogen and progestogen — oral pill, vaginal ring and transdermal patch — efficacy is high, but adherence-dependent. These methods provide menstrual regularity and rapid return to fertility, features valued by many users. However, it is essential to recognise the major contraindications related to oestrogens: migraine with aura, previous venous thromboembolism, uncontrolled hypertension, breast cancer and heavy smoking after the age of 35. In these contexts, progestogen-only or intrauterine methods are safer options.
Oral progestogen
Finally, the oral progestogen is a daily-use alternative, with adequate efficacy and rapid return to fertility. It is compatible with breastfeeding and may be useful when combined methods are contraindicated, although it may be associated with irregular cycles.
Key messages
Overall, the table illustrates three central messages: first, long-acting methods with low user dependence are the most effective in real-world practice; second, methods containing oestrogens require careful assessment of thrombotic and cardiovascular risk; and third, method choice should be personalised, integrating efficacy, menstrual effects, comorbidities, breastfeeding, future fertility and the user’s preferences.